DOuble SEquential External Defibrillation for Refractory VF Pilot Study (DOSE-VF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03249948 |
Recruitment Status :
Completed
First Posted : August 15, 2017
Last Update Posted : March 18, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ventricular Fibrillation | Procedure: Vector change defibrillation Procedure: Double-sequential defibrillation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 173 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | This is a cluster randomized study, with cluster units defined by EMS agency. Each cluster will crossover at three times during the one year trial so that each agency will spend 4 months in each arm of the study. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation - DOSE VF Pilot Study |
Actual Study Start Date : | March 5, 2018 |
Actual Primary Completion Date : | September 10, 2019 |
Actual Study Completion Date : | March 12, 2020 |
Arm | Intervention/treatment |
---|---|
No Intervention: Standard defibrillation
All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
|
|
Vector change defibrillation
The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
|
Procedure: Vector change defibrillation
Defibrillation using pad placement in anterior-posterior position. |
Double-sequential defibrillation
The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
|
Procedure: Double-sequential defibrillation
Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
Other Names:
|
- Return of spontaneous circulation (ROSC) [ Time Frame: 1 day ]Binary outcome of whether or not patient returned to spontaneous circulation
- Feasibility of double sequential external defibrillation [ Time Frame: Day 1 ]80% or greater of patients receiving proper randomization and 80% or greater receiving an intervention shock prior to shock 6
- VF termination after first interventional shock [ Time Frame: 1 day ]Cessation of the VF waveform on defibrillator monitor at first rhythm analysis post interventional or standard shock. The interpretation will occur after three standard shocks have failed to terminate VF.
- VF termination inclusive of all interventional shocks [ Time Frame: 1 day ]Cessation of the VF waveform on defibrillator monitor at any rhythm analysis post interventional or standard shock. The interpretation will occur after three standard shocks have failed to terminate VF.
- Number of defibrillation attempts to obtain ROSC [ Time Frame: 1 day ]Total number of shocks required to achieve the first ROSC during resuscitation, inclusive of the first three standard shocks.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ≥18 years of age, non-traumatic cardiac arrest of presumed cardiac etiology, presenting rhythm to EMS of ventricular fibrillation; no ROSC or non VF rhythm after three consecutive EMS shocks.
Exclusion Criteria:
- Traumatic cardiac arrest, patients with pre-existing do not resuscitate orders, presumed pregnancy, patients in recurrent ventricular fibrillation (defined as those with a secondary presentation of VF (not the presenting rhythm) or those presenting in VF but did not receive three consecutive defibrillation attempts).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03249948
Canada, Ontario | |
Peel Regional Paramedic Service | |
Brampton, Ontario, Canada | |
Halton Region Paramedic Services | |
Oakville, Ontario, Canada | |
County of Simcoe Paramedic Services | |
Simcoe, Ontario, Canada | |
Toronto Paramedic Services | |
Toronto, Ontario, Canada |
Principal Investigator: | Sheldon Cheskes, MD | Sunnybrook Centre for Prehospital Medicine |
Responsible Party: | Sunnybrook Health Sciences Centre |
ClinicalTrials.gov Identifier: | NCT03249948 |
Other Study ID Numbers: |
DOSE-VF-PILOT |
First Posted: | August 15, 2017 Key Record Dates |
Last Update Posted: | March 18, 2020 |
Last Verified: | March 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Ventricular Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |